EIF supports translational med with 25m
The EIF has invested 25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.
The EIF has invested 25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.
Following the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest 307m in the company’s producion site near Dublin.
UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to a current aggregate total of US $125m.
The Swiss biopharmaceutical industry is on the verge of record growth: This was demonstrated at the live Swiss Biotech Day in Basel.
EuropaBio has responded to the European Commissions public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.
Cardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Visus Therapeutics has baged a 20m stock financing to advance development of Brimochol for presbyopia
British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.